Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Receivables (2016 - 2025)

Anaptysbio filings provide 9 years of Receivables readings, the most recent being $33.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Receivables fell 16.96% year-over-year to $33.8 million, compared with a TTM value of $33.8 million through Dec 2025, down 16.96%, and an annual FY2025 reading of $33.8 million, down 16.96% over the prior year.
  • Receivables hit $33.8 million in Q4 2025 for Anaptysbio, down from $75.7 million in the prior quarter.
  • The five-year high for Receivables was $75.7 million in Q3 2025, with the low at $642000.0 in Q2 2021.
  • Median Receivables over the past 5 years was $3.2 million (2023), compared with a mean of $12.0 million.
  • The sharpest move saw Receivables tumbled 75.06% in 2021, then surged 520.62% in 2025.
  • Year by year, Receivables stood at $876000.0 in 2021, then skyrocketed by 61.99% to $1.4 million in 2022, then soared by 382.8% to $6.9 million in 2023, then soared by 495.02% to $40.8 million in 2024, then fell by 16.96% to $33.8 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $33.8 million, $75.7 million, and $21.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.